News Quantified

CRBP – corbus pharmaceuticals holdings, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology [Seeking Alpha]

Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength [Yahoo! Finance]

Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer [Yahoo! Finance]

Oppenheimer Holdings Inc.

Form 4 Corbus Pharmaceuticals For: Apr 10 Filed by: Moran Sean F.

Form DEFA14A Corbus Pharmaceuticals

Form 8-K Corbus Pharmaceuticals For: Apr 10

Form ARS Corbus Pharmaceuticals For: Dec 31

Form DEFA14A Corbus Pharmaceuticals

Top News Gainers

3/16 Form 10-K Corbus Pharmaceuticals For: Dec 31 23.8%

3/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) is now covered by analysts at Nomura. They set a "buy" rating and a $112.00 price target on the stock. 12.7%

3/12 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q4 2019 Earnings Call Transcript [The Motley Fool] 11.8%

3/18 Form 4 Corbus Pharmaceuticals For: Mar 17 Filed by: Millian Craig Stuart 10.0%

3/9 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Moran Sean F. 9.6%

3/18 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.3%

4/9 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.7%

5/10 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock. 5.2%

3/28 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.0%

1/14 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.8%

Top News Decliners

12/9 Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System -9.1%

5/9 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus 0.020 ActVsEst (0.450) - Miss -8.9%

8/8 Form 8-K Corbus Pharmaceuticals For: Aug 08 -8.7%

2/26 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.75 price target on the stock. -8.5%

11/7 Q3/2019 9/30/2019 EPS -0.320 ZacksConsensus -0.360 ActVsEst 0.040 - Beat -8.0%

3/12 Q4/2019 12/31/2019 EPS -0.410 ZacksConsensus -0.340 ActVsEst (0.070) - Miss -7.3%

3/10 Form 4 Corbus Pharmaceuticals For: Mar 06 Filed by: Salzmann Peter -6.8%

2/6 Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock -6.4%

8/13 Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $7.00 price target on the stock. -6.2%

3/5 Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020 -6.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day